IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

FAVALLI, ENNIO GIULIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 5.321
NA - Nord America 5.141
EU - Europa 4.871
SA - Sud America 843
AF - Africa 197
OC - Oceania 32
Continente sconosciuto - Info sul continente non disponibili 9
Totale 16.414
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.882
SG - Singapore 1.796
CN - Cina 1.759
IT - Italia 1.259
DE - Germania 704
GB - Regno Unito 698
BR - Brasile 646
HK - Hong Kong 538
RU - Federazione Russa 433
SE - Svezia 329
FR - Francia 257
IN - India 257
NL - Olanda 251
IE - Irlanda 204
CA - Canada 170
FI - Finlandia 154
VN - Vietnam 154
ID - Indonesia 144
JP - Giappone 139
TR - Turchia 132
ES - Italia 130
CI - Costa d'Avorio 83
AR - Argentina 70
KR - Corea 60
MX - Messico 57
UA - Ucraina 55
PL - Polonia 53
GR - Grecia 51
AT - Austria 49
DK - Danimarca 46
IQ - Iraq 41
BD - Bangladesh 39
TW - Taiwan 38
CH - Svizzera 33
CO - Colombia 31
RO - Romania 30
AU - Australia 28
BE - Belgio 28
PE - Perù 27
ZA - Sudafrica 27
IL - Israele 26
PK - Pakistan 24
CZ - Repubblica Ceca 22
UZ - Uzbekistan 21
EC - Ecuador 20
PT - Portogallo 20
CL - Cile 19
EG - Egitto 19
IR - Iran 19
PH - Filippine 19
EU - Europa 18
MA - Marocco 18
MY - Malesia 16
SA - Arabia Saudita 16
TH - Thailandia 16
VE - Venezuela 16
HU - Ungheria 10
NO - Norvegia 10
DZ - Algeria 9
LT - Lituania 9
BG - Bulgaria 8
HR - Croazia 8
JO - Giordania 8
KE - Kenya 8
PA - Panama 8
TN - Tunisia 8
AE - Emirati Arabi Uniti 7
UY - Uruguay 7
BA - Bosnia-Erzegovina 6
ET - Etiopia 6
PY - Paraguay 6
KW - Kuwait 5
KZ - Kazakistan 5
LB - Libano 5
AM - Armenia 4
AP - ???statistics.table.value.countryCode.AP??? 4
AZ - Azerbaigian 4
CR - Costa Rica 4
CY - Cipro 4
DO - Repubblica Dominicana 4
JM - Giamaica 4
KG - Kirghizistan 4
LA - Repubblica Popolare Democratica del Laos 4
NZ - Nuova Zelanda 4
SC - Seychelles 4
TT - Trinidad e Tobago 4
MD - Moldavia 3
PR - Porto Rico 3
SI - Slovenia 3
SY - Repubblica araba siriana 3
EE - Estonia 2
GA - Gabon 2
MO - Macao, regione amministrativa speciale della Cina 2
NG - Nigeria 2
NI - Nicaragua 2
NP - Nepal 2
OM - Oman 2
QA - Qatar 2
SK - Slovacchia (Repubblica Slovacca) 2
A2 - ???statistics.table.value.countryCode.A2??? 1
Totale 16.403
Salva come PNG Salva come JPEG
Città #
Singapore 900
Ashburn 673
Hong Kong 440
Southend 430
Chandler 388
Milan 382
Dallas 292
Beijing 262
Hanover 248
Dublin 198
Santa Clara 191
Princeton 179
Los Angeles 178
Council Bluffs 166
Fairfield 165
Frankfurt am Main 161
Hefei 148
Guangzhou 140
Wilmington 134
Redwood City 123
Bengaluru 114
San Jose 113
Jakarta 107
Helsinki 98
New York 94
Seattle 92
Moscow 90
Houston 89
Abidjan 83
Cambridge 82
Toronto 80
Woodbridge 80
São Paulo 70
Buffalo 69
Rome 68
Munich 66
Shanghai 65
Tokyo 61
Central District 55
Ann Arbor 50
Boardman 50
Cangzhou 50
Des Moines 50
Ho Chi Minh City 49
London 46
Nanjing 42
Istanbul 40
Madrid 40
Chicago 35
Jacksonville 34
Hanoi 33
Changsha 32
Dearborn 32
Montreal 32
Phoenix 31
San Diego 31
Bologna 28
Columbus 27
Jinan 27
Shenyang 27
Grafing 26
Berlin 24
Medford 24
Amsterdam 22
Seoul 22
Sunnyvale 22
Turin 22
Vienna 22
Athens 21
The Dalles 21
Turku 21
Edinburgh 20
Redmond 19
San Francisco 19
Serra 19
Belo Horizonte 18
Fuzhou 18
Nuremberg 18
Rho 18
Rio de Janeiro 18
Taipei 18
Porto Alegre 17
Atlanta 16
Bogotá 16
Lappeenranta 16
Shenzhen 16
Wuhan 16
Zhengzhou 16
Zurich 16
Düsseldorf 15
Florence 15
Gdansk 15
Tashkent 15
Paris 14
Quanzhou 14
Tianjin 14
Warsaw 14
Wroclaw 14
Boston 13
Denver 13
Totale 8.877
Salva come PNG Salva come JPEG
Nome #
Biomarkers in psoriatic arthritis : a systematic literature review 1.399
Eight-year retention rate of first-line tumor necrosis factor inhibitors in spondyloarthritis : A multi-center retrospective analysis 401
The Expanded Risk Score in Rheumatoid Arthritis (ERS-RA): performance of a disease-specific calculator in comparison with the traditional prediction scores in the assessment of the 10-year risk of cardiovascular disease in patients with rheumatoid arthrit 387
Switch or swap strategy in rheumatoid arthritis patients failing TNF inhibitors? Results of a modified Italian Expert Consensus 365
Are patients with systemic lupus erythematosus at increased risk for COVID-19? 350
Activation of inflammation, coagulation and fibrinolysis in patients with Rheumatoid Arthritis : inhibition by Tumor Necrosis Factor alpha blockade 329
Prédicteurs de la réponse aux traitements anti-TNF chez les patients ayant une polyarthrite rhumatoïde avec des scores DAS28 modérés ou élevés 304
Real-world 6 and 12-month drug retention, remission and response rates of secukinumab in 2,017 psoriatic arthritis patients in 13 European countries 282
Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis : effects of tumor necrosis factor-alpha blockade 271
COVID-19 infection and rheumatoid arthritis: Faraway, so close! 267
Increasing the threshold for patient global assessment in defining remission may have a different impact in patients with early and established rheumatoid arthritis 246
Clinical management of patients with rheumatoid arthritis during the COVID-19 pandemic 218
Baricitinib for COVID-19: a suitable treatment? 217
Haemostatic and inflammatory biomarkers in patients with rheumatoid arthritis : effect of tumor necrosis factor alpha blockade 206
Comments on “Short-term reasons for withdrawal and adverse events associated with apremilast therapy for psoriasis in real-world practice compared with in clinical trials : a multicenter retrospective study” 200
Effetto della terapia con infliximab sui marcatori di infiammazione, coagulazione e fibrinolisi nell’artrite reumatoide 198
Haemostatic and inflammatory biomarkers in patients with active Rheumatoid Arthritis : effects of Tumor Necrosis Factor alpha blockade 195
Retrospective evaluation of patient profiling and effectiveness of apremilast in an Italian multicentric cohort of psoriatic arthritis patients 189
Effect of tumor necrosis factor alpha blockade on inflammatory and haemostatic biomarkers in patients with rheumatoid arthritis 182
Potential short-term air pollution effects on rheumatoid arthritis activity in metropolitan areas in the North of Italy : A cross-sectional study 180
Reduction of haemostatic and inflammatory biomarkers by tumor necrosis factor-alpha bockade in patients with rheumatoid arthritis 172
Immunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Populations 169
Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease in a cohort of patients treated with TNF-alpha inhibitors 168
Role of antimalarials in COVID-19 : observational data from a cohort of rheumatic patients 165
The impact of EMA recommendations on the real-life use of Janus kinases inhibitors for rheumatoid arthritis: the Expanded Risk Score in RA as a tool to quantify the risk of cardiovascular events 164
COVID-19 and what pediatric rheumatologists should know: A review from a highly affected country 159
Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA 142
Tight control in patients with rheumatoid arthritis treated with targeted therapies across the COVID-19 pandemic era 139
Incidence and clinical course of COVID-19 in patients with connective tissue diseases: a descriptive observational analysis 136
Incidence of COVID-19 in patients with rheumatic diseases treated with targeted immunosuppressive drugs: what can we learn from observational data? 131
Ensuring tight control in patients with rheumatoid arthritis treated with targeted therapies during the COVID-19 pandemic using a telehealth strategy 127
The role of biologic agents in damage progression in rheumatoid arthritis: indirect comparison of data coming from randomized clinical trials 126
The management of first-line biologic therapy failures in rheumatoid arthritis : current practice and future perspectives 126
Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors 124
Effects of anti-TNF alpha drugs on disability in patients with rheumatoid arthritis: Long-term real-life data from the Lorhen registry 121
Biologic therapy and spinal radiographic progression in patients with axial spondyloarthritis : a structured literature review 121
Prevalence of COVID infections in a population of rheumatic patients from Lombardy and Marche treated with biological drugs or small molecules : A multicentre retrospective study 121
Upadacitinib and filgotinib: The role of JAK1 selective inhibition in the treatment of rheumatoid arthritis 120
The role of concomitant methotrexate dosage and maintenance over time in the therapy of rheumatoid arthritis patients treated with adalimumab or etanercept : Retrospective analysis of a local registry 118
The Use of Rheumatic Disease Comorbidity Index for Predicting Clinical Response and Retention Rate in a Cohort of Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Alpha Inhibitors 116
Difficult-to-treat psoriatic arthritis: refining the definition using a statistical model in a real-life cohort 115
Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study) 115
Is there really room for anti-rheumatic drugs in the treatment of COVID-19? 113
Sex and Management of Rheumatoid Arthritis 113
Low frequency of disease flare in patients with rheumatic musculoskeletal diseases who received SARS-CoV-2 mRNA vaccine 112
A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: Focus on interchangeability 112
Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis 112
Novel Mechanisms of Action of the Biologicals in Rheumatic Diseases 111
The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study 111
Predictors of response to anti-TNF therapy in RA patients with moderate or high DAS28scores 109
Real-world experience of tocilizumab in rheumatoid arthritis : sub-analysis of data from the Italian biologics’ register GISEA 108
Expert consensus on the treatment of patients with adult-onset still's disease with the goal of achieving an early and long-term remission 108
Immune response to SARS-COV-2 infection in patients with rheumatic musculoskeletal diseases: the mainstream study 107
The comparison of effects of biologic agents on rheumatoid arthritis damage progression is biased by period of enrolment: data from a systematic review and meta-analysis 107
Spotlight on mavrilimumab for the treatment of rheumatoid arthritis : Evidence to date 106
High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: Data from GISEA, the Italian biologics register 105
Tocilizumab in the treatment of rheumatoid arthritis : An evidence-based review and patient selection 105
Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis 105
Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations : similarities and differences 105
Multidisciplinary consensus on the diagnosis and management of patients with atypical Hemolytic Uremic Syndrome (complement-mediated TMA): recommendations from Italian scientific societies, patient associations and regulators 104
An Italian Disease-Based Registry of Axial and Peripheral Spondyloarthritis : The SIRENA Study 104
The profiling of axial spondyloarthritis patient candidate to a biologic therapy : consensus from a Delphi-panel of Italian experts 102
The 12-item psoriatic arthritis impact of disease questionnaire : Construct validity, reliability, and interpretability in a clinical setting 101
Sarilumab : patient-reported outcomes in rheumatoid arthritis 100
Erratum to: Anti-CarP antibodies as promising marker to measure joint damage and disease activity in patients with rheumatoid arthritis 99
Targeting Granulocyte-Monocyte Colony-Stimulating Factor Signaling in Rheumatoid Arthritis: Future Prospects 99
Short-term exposure to outdoor air pollutants and rheumatoid arthritis activity in metropolitan areas in the North of Italy 98
Treatment comparison in rheumatoid arthritis : head-to-head trials and innovative study designs 97
Retention rate of tumor necrosis factor inhibitors, anti-interleukin 17, and anti-interleukin 12/23 drugs in a single-center cohort of psoriatic arthritis patients 96
Biologics or Janus Kinase Inhibitors in Rheumatoid Arthritis Patients Who are Insufficient Responders to Conventional Anti-Rheumatic Drugs 95
Dr. Favalli, et al. reply 94
Use of rituximab in a multicentre cohort of patients with rheumatic diseases during the outbreak of novel SARS-COV-2 infection 92
Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors : real-life data from the LORHEN registry 91
TNF-α antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice 91
The role of methotrexate as combination therapy with etanercept in rheumatoid arthritis: Retrospective analysis of a local registry 91
The change over time in the prescription pattern of the first targeted drug after failure of conventional therapy in patients with rheumatoid arthritis: a 20-year real-world experience 90
Effect of neridronate on axial involvement in patients with spondyloarthritis when biologics are not possible. Results of a monocentric study 90
Clinical evaluation of a novel chemiluminescent immunoassay for the detection of anti-citrullinated peptide antibodies 90
Efficacy and safety of anti-TNF agents in the Lombardy rheumatoid arthritis network (LORHEN) = Efficacia e sicurezza degli agenti anti-TNF nel registro Lombardo (LORHEN) 88
Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis : real-life data from the Italian LORHEN Registry 87
Anti-TNFα therapy in a cohort of rheumatoid arthritis patients : clinical outcomes 85
Persistence, switch rates, drug consumption and costs of biological treatment of rheumatoid arthritis: An observational study in Italy 84
Retention rate of biologic and targeted synthetic anti-rheumatic drugs in elderly rheumatoid arthritis patients: data from GISEA registry 84
Vitamin D and spondyloarthritis: Review of the literature 83
Mavrilimumab: a unique insight and update on the current status in the treatment of rheumatoid arthritis 81
Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: data from the LORHEN registry 80
Lessons learned from the preclinical discovery and development of sarilumab for the treatment of rheumatoid arthritis 79
Anti-CarP antibodies as promising marker to measure joint damage and disease activity in patients with rheumatoid arthritis 79
Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab : results from the Italian GISEA registry 79
Clinical pharmacology of filgotinib in the treatment of rheumatoid arthritis: current insights 77
Recommendations for the management of pulmonary fungal infections in patients with rheumatoid arthritis 76
Il nodulo reumatoide 76
One-Third of European Patients With Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment 76
Arthritis in Systemic Lupus Erythematosus: From 2022 International GISEA/OEG Symposium 75
Certolizumab Pegol Treatment in Patients with Axial-Spondyloarthritis-Associated Acute Anterior Uveitis: a Narrative Review 73
Is there a need for new thresholds to define remission and low disease activity by disease activity score 28 calculated with C reactive protein? real life data from a local registry 72
From Bench to Bedside in Rheumatoid Arthritis from the “2022 GISEA International Symposium” 71
Axial Spondyloarthritis: Reshape the Future—From the “2022 GISEA International Symposium” 70
Change over time in the pattern of clinical response to first-line biologic drugs in patients with rheumatoid arthritis: Observational data in a real-life setting 70
Inflammatory correlates of the Patient Global Assessment of Disease Activity vary in relation to disease duration and autoantibody status in patients with rheumatoid arthritis 69
Totale 14.768
Salva come PNG Salva come JPEG
Categoria #
all - tutte 51.002
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 51.002
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021598 0 0 0 0 0 0 79 125 111 103 99 81
2021/20221.516 58 55 65 99 100 82 78 277 201 139 115 247
2022/20231.742 217 144 138 151 189 313 93 108 169 38 142 40
2023/20241.359 49 93 79 111 345 105 82 65 50 79 109 192
2024/20254.082 106 433 175 333 328 194 245 366 250 383 430 839
2025/20264.483 739 593 915 780 735 541 180 0 0 0 0 0
Totale 17.060